Fasted C-Peptide Distribution and Associated Clinical Factors in Adults With Longstanding Type 1 Diabetes: Analysis of the Canadian Study of Longevity in Type 1 Diabetes.

C-peptide Canadian Study of Longevity in Type 1 Diabetes Hypoglycemia Fear Survey Hypoglycemia Fear Survey (soit l’enquête sur la crainte du risque de survenue d’hypoglycémies) diabète de type 1 insuline quotidienne totale peptide C total daily insulin type 1 diabetes étude canadienne sur la longévité des diabétiques de type 1

Journal

Canadian journal of diabetes
ISSN: 2352-3840
Titre abrégé: Can J Diabetes
Pays: Canada
ID NLM: 101148810

Informations de publication

Date de publication:
Mar 2024
Historique:
received: 29 11 2022
revised: 01 08 2023
accepted: 02 11 2023
medline: 18 3 2024
pubmed: 10 11 2023
entrez: 9 11 2023
Statut: ppublish

Résumé

Although insulin production is reportedly retained in many people with longstanding type 1 diabetes (T1D), the magnitude and relevance of connecting peptide (C-peptide) production are uncertain. In this study, we aimed to define fasted C-peptide distributions and associated clinical factors. In a cross-sectional analysis of the Canadian Study of Longevity, fasted serum and urinary C-peptide was measured in 74 patients with longstanding T1D (duration ≥50 years) and 75 age- and sex-matched controls. Extensive phenotyping for complications was performed and patient-reported variables were included. C-peptide distributions were analyzed, and multivariable logistic regression was used to assess the variable association in participants with T1D. The 74 participants with T1D had a mean age of 66±8 years, a disease duration of 54 (interquartile range 52 to 58) years, and a glycated hemoglobin (A1C) of 7.4%±0.8% (56.8±9.15 mmol/mol). The 75 controls had a mean age of 65±8 years and an A1C of 5.7%±0.4% (38.4±4.05 mmol/mol). Participants with T1D had lower fasted serum C-peptide than controls (0.013±0.022 vs 1.595±1.099 nmol/L, p<0.001). Of the participants with T1D, C-peptide was detectable in 30 of 73 (41%) serum samples, 32 of 74 (43%) urine samples, and 48 of 74 (65%) for either serum or urine. The variables independently associated with detectable serum or urinary C-peptide were lower total daily insulin requirement (odds ratio 2.351 [for 1 lower unit/kg], p=0.013) and lower hypoglycemia worry score (odds ratio 1.059 [for 1 point lower on the worry subscore of the Hypoglycemia Fear Survey], p=0.030). Although detectable C-peptide in longstanding diabetes was common, the magnitude of concentration was extremely low when compared with age- and sex-matched controls. Despite minimal detectability, its presence is validated by lower insulin requirements and strongly associated with lower hypoglycemia worry.

Identifiants

pubmed: 37944665
pii: S1499-2671(23)00710-4
doi: 10.1016/j.jcjd.2023.11.001
pii:
doi:

Substances chimiques

C-Peptide 0
Glycated Hemoglobin 0
Insulin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

89-96

Informations de copyright

Copyright © 2023 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved.

Auteurs

Sebastien O Lanctôt (SO)

Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Ontario, Canada.

Leif Erik Lovblom (LE)

Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Ontario, Canada.

Evan J H Lewis (EJH)

Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Ontario, Canada.

Michelle Morris (M)

Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Ontario, Canada.

Nancy Cardinez (N)

Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Ontario, Canada.

Daniel Scarr (D)

Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Ontario, Canada.

Abdulmohsen Bakhsh (A)

Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Ontario, Canada; Kidney & Pancreas Health Centre, Organ Transplant Centre of Excellence, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.

Mohammad I Abuabat (MI)

Internal Medicine and Critical Care Department, King Abdullah bin Abdulaziz University Hospital, Princess Norah University, Riyadh, Saudi Arabia.

Julie A Lovshin (JA)

Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Yuliya Lytvyn (Y)

Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Geneviève Boulet (G)

Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Ontario, Canada.

Alexandra Bussières (A)

Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke, Québec, Canada.

Michael H Brent (MH)

Faculty of Medicine, Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada.

Narinder Paul (N)

Joint Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada; Department of Medical Imaging, Western University, London, Ontario, Canada.

Vera Bril (V)

Division of Neurology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada.

David Z I Cherney (DZI)

Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Bruce A Perkins (BA)

Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Ontario, Canada; Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: bruce.perkins@sinaihealth.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH